Those familiar with the cannabis space will likely be familiar with 'Rick Simpson Oil', or what used to be known as 'hash oil'. This oil is a concentrate of oil from the cannabis plant that contains THC, CBD, and a host of 100+ other cannabinoids and cannabinoid like substances that are extracted from the raw plant material. Cannabinoids all have unique chemical structures and medicinal properties that range from anti-emetic to anti-epileptic.
The study referred to in the above paragraph suggests that the high dose cannabinoids flood the body, bypassing the CB1 and CB2 receptors through overflow and provide additional therapeutic benefits for fighting cancer via 'yet unkown' receptors. They proffer the idea that other G coupled protein receptors (GPR55) are involved and that is likely the case. However, additional receptors (PPAR) seem to also be involved and they are the nuclear receptors.
In conclusion, the above referenced randomized study provides preliminary evidence that 1:1 CBD:THC offers some efficacy in patients with recurrent GBM when used as an adjunct to dose-intense temozolomide and confirms the safety and feasibility of individualized dosing.
Look for further clinical evidence of the efficacy of cannabinoid therapy in cancer in the coming months from the biotech world.
NW University Study Shows Pediatric Brain Tumors Shrunk by Cannabinoids in the Body
January 30, 2017
The ECS and the Runner's High
November 11, 2015
Cannabis Treats Brain Cancer Effectively in FDA Trial for Humans